TriSalus Life Sciences, Inc. (TLSI)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch TLSI
See up to 3 months of TLSI. The 7-day demo opens the 1M and 3M ranges and puts TLSI on your watchlist.
Start 7-day demoLatest TLSI insider trades
About TriSalus Life Sciences, Inc. (TLSI)
The SEC lists TriSalus Life Sciences, Inc. under CIK 0001826667, in surgical and medical instruments and apparatus. We track it alongside the rest of the Health Care sector.
TLSI Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 3 | 937 | $4K |
| Tax withholding / forfeiture | 1 | 2,693 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
TLSI insider transactions (Form 4)
5450 Form 4 filings on record, the earliest from Nov 15, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Bryan F. Cox - Officer | Open-market sale | Common Stock | 296 footnote F1 | $4.39 | $1K | |
| ||||||
| Richard Marshak - Officer | Open-market sale | Common Stock | 325 footnote F1 | $4.39 | $1K | |
| ||||||
| Jennifer Stevens - Officer | Open-market sale | Common Stock | 316 footnote F1 | $4.39 | $1K | |
| ||||||
 Mary T. Szela - Officer | Tax withholding / forfeiture | Common Stock | 2,693 footnote F1 | $4.38 | $12K | |
| ||||||
| David Patience - Officer | Tax withholding / forfeiture | Common Stock | 14,650 footnote F1 | $4.46 | $65K | |
| ||||||
| Mary T. Szela - Officer | Grant or award | Common Stock | 3,990 footnote F1 | $3.87 | $15K | |
| ||||||
| Richard Marshak - Officer | Grant or award | Common Stock | 561 footnote F1 | $3.87 | $2K | |
| ||||||
| Richard Henry Marshall - Officer | Grant or award | Employee Stock Option (right to buy) | 120,000 | $0.00 | - | |
| Richard Henry Marshall - Officer | Grant or award | Common Stock | 60,000 footnote F1 | $0.00 | - | |
| ||||||
| Richard Marshak - Officer | Open-market sale | Common Stock | 543 footnote F1 | $2.67 | $1K | |
| ||||||
| Mats Wahlstrom - Director | Open-market purchase | Common Stock | 60,000 | $2.53 footnote F1 | $152K | |
| ||||||
| Michael P. Stansky - Director | Open-market purchase | Common Stock | 410,000 | $2.50 footnote F1 | $1.02M | |
| Michael P. Stansky - Director | Open-market purchase | Common Stock | 200,000 | $2.50 footnote F2 | $500K | |
| ||||||
| Mary T. Szela - Officer | Open-market purchase | Common Stock | 39,682 | $2.59 footnote F2 | $103K | |
| ||||||
| David Patience - Officer | Open-market purchase | Common Stock | 7,100 | $2.43 | $17K | |
| Gary B. Gordon - Director | Open-market purchase | Common Stock | 10,000 | $2.46 | $25K | |
| Kerry R. Hicks - Director | Grant or award | Common Stock | 28,201 footnote F1 | $0.00 | - | |
| Kerry R. Hicks - Director | Grant or award | Director Stock Option (right to buy) | 56,403 | $0.00 | - | |
| ||||||
| Mats Wahlstrom - Director | Grant or award | Common Stock | 37,602 footnote F1 | $0.00 | - | |
| Mats Wahlstrom - Director | Grant or award | Common Stock | 34,226 footnote F2 | $0.00 | - | |
| Mats Wahlstrom - Director | Grant or award | Director Stock Option (right to buy) | 75,204 | $0.00 | - | |
| ||||||
| Gary B. Gordon - Director | Grant or award | Common Stock | 28,201 footnote F1 | $0.00 | - | |
| Gary B. Gordon - Director | Grant or award | Common Stock | 24,553 footnote F2 | $0.00 | - | |
| Gary B. Gordon - Director | Grant or award | Director Stock Option (right to buy) | 56,403 | $0.00 | - | |
| ||||||
 David J. Matlin - Director | Grant or award | Common Stock | 28,201 footnote F1 | $0.00 | - | |
| David J. Matlin - Director | Grant or award | Common Stock | 23,065 footnote F2 | $0.00 | - | |
| David J. Matlin - Director | Grant or award | Director Stock Option (right to buy) | 56,403 | $0.00 | - | |
| ||||||
| William Valle - Director | Grant or award | Common Stock | 28,201 footnote F1 | $0.00 | - | |
| William Valle - Director | Grant or award | Common Stock | 24,553 footnote F2 | $0.00 | - | |
| William Valle - Director | Grant or award | Director Stock Option (right to buy) | 56,403 | $0.00 | - | |
| ||||||
| Michael P. Stansky - Director | Grant or award | Common Stock | 23,501 footnote F1 | $0.00 | - | |
| Michael P. Stansky - Director | Grant or award | Common Stock | 20,089 footnote F2 | $0.00 | - | |
| Michael P. Stansky - Director | Grant or award | Director Stock Option (right to buy) | 47,003 | $0.00 | - | |
| ||||||
| Frankenius Equity AB - 10% Owner | Other | Common Stock | 759,000 footnote F1 | $0.00 | - | |
| Frankenius Equity AB - 10% Owner | Other | Series A Convertible Preferred Stock | 230,000 footnote F3 | $0.00 | - | |
| ||||||
| David J. Matlin - Director | Other | Common Stock | 330,000 footnote F1 | $0.00 | - | |
| David J. Matlin - Director | Other | Series A Preferred Stock | 100,000 footnote F3 | $0.00 | - | |
| ||||||
| Jodi Devlin - Officer | Open-market sale | Common Stock | 1,162 footnote F1 | $4.13 | $5K | |
| Jodi Devlin - Officer | Open-market sale | Common Stock | 1,772 footnote F1 | $4.09 | $7K | |
| Jodi Devlin - Officer | Open-market sale | Common Stock | 273 footnote F1 | $4.12 | $1K | |
| ||||||
| Bryan F. Cox - Officer | Open-market sale | Common Stock | 1,138 footnote F1 | $4.13 | $5K | |
| Bryan F. Cox - Officer | Open-market sale | Common Stock | 1,467 footnote F1 | $4.09 | $6K | |
| Bryan F. Cox - Officer | Open-market sale | Common Stock | 579 footnote F1 | $4.12 | $2K | |
| ||||||
| Richard Marshak - Officer | Open-market sale | Common Stock | 1,449 footnote F1 | $4.13 | $6K | |
| Richard Marshak - Officer | Open-market sale | Common Stock | 1,589 footnote F1 | $4.09 | $6K | |
| Richard Marshak - Officer | Open-market sale | Common Stock | 419 footnote F1 | $4.12 | $2K | |
| ||||||
| Jennifer Stevens - Officer | Open-market sale | Common Stock | 1,204 footnote F1 | $4.13 | $5K | |
| Jennifer Stevens - Officer | Open-market sale | Common Stock | 1,552 footnote F1 | $4.09 | $6K | |
| Jennifer Stevens - Officer | Open-market sale | Common Stock | 774 footnote F1 | $4.12 | $3K | |
| ||||||
| Mary T. Szela - Officer | Open-market sale | Common Stock | 4,358 footnote F1 | $4.13 | $18K | |
| Mary T. Szela - Officer | Open-market sale | Common Stock | 15,944 footnote F1 | $3.85 | $61K | |
| ||||||
| David Patience - Officer | Open-market purchase | Common Stock | 3,657 | $4.10 | $15K | |
| Gary B. Gordon - Director | Open-market purchase | Common Stock | 9,756 | $4.10 | $40K | |
| William Valle - Director | Open-market purchase | Common Stock | 30,487 | $4.10 | $125K | |
Item 8.01, 9.01
Item 2.02, 9.01
Item 5.07
Item 2.02, 9.01
TLSI insider trading FAQ
What is the latest insider trade for TLSI?
TriSalus Life Sciences, Inc. (TLSI) had 4 insider filings in the last 90 days, with the most recent on 2026-10-07. The full record for TLSI runs to 50 Form 4 filings, the earliest from 2024-11-15. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying TLSI stock?
No insider purchases of TLSI were filed in the last 90 days. 16 purchases are on record for this company.
How many insiders are selling TLSI stock?
3 insider sales of TLSI were filed in the last 90 days, totaling $4K.
Where can I see TLSI SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects TLSI Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Bryan F. Cox view on EDGAR
- - Richard Marshak view on EDGAR
- - Jennifer Stevens view on EDGAR
- - Mary T. Szela view on EDGAR
- - David Patience view on EDGAR
- - Mary T. Szela view on EDGAR
- - Richard Marshak view on EDGAR
- - Richard Henry Marshall view on EDGAR
- - Richard Marshak view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Insider activity in Health Care
- Where TLSI's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow TLSI with a 7-day demo
- TLSI on your watchlist
- Every TLSI Form 4 filing on record
- Up to 3 months of TLSI price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
